Analysis of COQ2 gene in multiple system atrophy

Molecular Neurodegeneration

Owen A Ross²  Dennis W Dickson²  Zbigniew K Wszolek³  William P Cheshire³  Ryan Uitti³  Neill Graff-Radford³  Rosa Rademakers²  Yan Asmann²  Xue Wang²  Oswaldo Lorenzo-Betancor²  Ronald L Walton²  Catherine Labbé²  Alexandra I Soto-Ortolaza²  Sruti Rayaprolu²  Michael G Heckman¹  Shinsuke Fujioka³  Kotaro Ogaki² 

[1] Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA;Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA;Department of Neurology, Mayo Clinic, Jacksonville, FL, USA

关键词: CoQ10 deficiency;    Genetics;    Multiple system atrophy;    COQ2;   

Others  :  1132685
DOI  :  10.1186/1750-1326-9-44

 received in 2014-08-26, accepted in 2014-10-27,  发布年份 2014

【 摘 要 】

Background

Loss of function COQ2 mutations results in primary CoQ10 deficiency. Recently, recessive mutations of the COQ2 gene have been identified in two unrelated Japanese families with multiple system atrophy (MSA). It has also been proposed that specific heterozygous variants in the COQ2 gene may confer susceptibility to sporadic MSA. To assess the frequency of COQ2 variants in patients with MSA, we sequenced the entire coding region and investigated all exonic copy number variants of the COQ2 gene in 97 pathologically-confirmed and 58 clinically-diagnosed MSA patients from the United States.

Results

We did not find any homozygous or compound heterozygous pathogenic COQ2 mutations including deletion or multiplication within our series of MSA patients. In two patients, we identified two heterozygous COQ2 variants (p.S54W and c.403 + 10G > T) of unknown significance, which were not observed in 360 control subjects. We also identified one heterozygous carrier of a known loss of function p.S146N substitution in a severe MSA-C pathologically-confirmed patient.

Conclusions

The COQ2 p.S146N substitution has been previously reported as a pathogenic mutation in primary CoQ10 deficiency (including infantile multisystem disorder) in a recessive manner. This variant is the third primary CoQ10 deficiency mutation observed in an MSA case (p.R387X and p.R197H). Therefore it is possible that in the heterozygous state it may increase susceptibility to MSA. Further studies, including reassessing family history in patients of primary CoQ10 deficiency for the possible occurrence of MSA, are now warranted to resolve the role of COQ2 variation in MSA.

【 授权许可】

   
2014 Ogaki et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Stefanova N, Bucke P, Duerr S, Wenning GK: Multiple system atrophy: an update. Lancet Neurol 2009, 8:1172-1178.
• [2]Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
• [3]Papp MI, Kahn JE, Lantos PL: Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989, 94:79-100.
• [4]The Multiple-System Atrophy Research Collaboration: Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013, 369:233-244.
• [5]Scalais E, Chafai R, Van Coster R, Bindl L, Nuttin C, Panagiotaraki C, Seneca S, Lissens W, Ribes A, Geers C, Smet J, De Meirleir L: Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). Eur J Paediatr Neurol 2013, 17:625-630.
• [6]Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, Emma F: COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007, 18:2773-2780.
• [7]Bujan N, Arias A, Montero R, Garcia-Villoria J, Lissens W, Seneca S, Espinos C, Navas P, De Meirleir L, Artuch R, Briones P, Ribes A: Characterization of CoQ biosynthesis in fibroblasts of patients with primary and secondary CoQ deficiency. J Inherit Metab Dis 2014, 37:53-62.
• [8]Dinwiddie DL, Smith LD, Miller NA, Atherton AM, Farrow EG, Strenk ME, Soden SE, Saunders CJ, Kingsmore SF: Diagnosis of mitochondrial disorders by concomitant next-generation sequencing of the exome and mitochondrial genome. Genomics 2013, 102:148-156.
• [9]McCarthy HJ, Bierzynska A, Wherlock M, Ognjanovic M, Kerecuk L, Hegde S, Feather S, Gilbert RD, Krischock L, Jones C, Sinha MD, Webb NJ, Christian M, Williams MM, Marks S, Koziell A, Welsh GI, Saleem MA, RADAR the UK SRNS Study Group: Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2013, 8:637-648.
• [10]Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S, Hirano M: A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006, 78:345-349.
• [11]Jakobs BS, van den Heuvel LP, Smeets RJ, de Vries MC, Hien S, Schaible T, Smeitink JA, Wevers RA, Wortmann SB, Rodenburg RJ: A novel mutation in COQ2 leading to fatal infantile multisystem disease. J Neurol Sci 2013, 326:24-28.
• [12]Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, Bacq D, de Lonlay P, Munnich A, Rotig A: Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest 2007, 117:765-772.
• [13]Schottlaender LV, Houlden H: Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014, 371:81.
• [14]Forsgren M, Attersand A, Lake S, Grunler J, Swiezewska E, Dallner G, Climent I: Isolation and functional expression of human COQ2, a gene encoding a polyprenyl transferase involved in the synthesis of CoQ. Biochem J 2004, 382:519-526.
• [15]Haft DH, Selengut JD, White O: The TIGRFAMs database of protein families. Nucleic Acids Res 2003, 31:371-373.
• [16]Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR, Heger A, Hetherington K, Holm L, Mistry J, Sonnhammer EL, Tate J, Punta M: Pfam: the protein families database. Nucleic Acids Res 2014, 42:D222-D230.
• [17]Jeon BS, Farrer MJ, Bortnick SF: Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014, 371:80.
• [18]Sharma M, Wenning G, Kruger R: Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014, 371:80-81.
• [19]Mitsui J, Tsuji S: Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014, 371:82-83.
• [20]Naini A, Lewis VJ, Hirano M, DiMauro S: Primary coenzyme Q10 deficiency and the brain. Biofactors 2003, 18:145-152.
• [21]Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Del Sorbo F, Schneider S, Bhatia KP, Gasser T: SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009, 65:610-614.
• [22]Ross OA, Vilarino-Guell C, Wszolek ZK, Farrer MJ, Dickson DW: Reply to: SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol 2010, 67:414-415.
• [23]Vilarino-Guell C, Soto-Ortolaza AI, Rajput A, Mash DC, Papapetropoulos S, Pahwa R, Lyons KE, Uitti RJ, Wszolek ZK, Dickson DW, Farrer MJ, Ross OA: MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 2011, 76:670-672.
• [24]Sasaki H, Emi M, Iijima H, Ito N, Sato H, Yabe I, Kato T, Utsumi J, Matsubara K: Copy number loss of (src homology 2 domain containing)-transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy. Mol Brain 2011, 4:24. BioMed Central Full Text
• [25]Ferguson MC, Garland EM, Hedges L, Womack-Nunley B, Hamid R, Phillips JA, Shibao CA, Raj SR, Biaggioni I, Robertson D: SHC2 gene copy number in multiple system atrophy (MSA). Clin Auton Res 2014, 24:25-30.
• [26]Lopez LC, Quinzii CM, Area E, Naini A, Rahman S, Schuelke M, Salviati L, Dimauro S, Hirano M: Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLoS One 2010, 5:e11897.
• [27]Rajput A, Vilarino-Guell C, Rajput ML, Ross OA, Soto-Ortolaza AI, Lincoln SJ, Cobb SA, Heckman MG, Farrer MJ: Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. Mov Disord 2009, 24:2411-2414.
• [28]Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
• [29]Ng PC, Henikoff S: SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814.
• [30]Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C: Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009, 37:e67.
• [31]Ren J, Wen L, Gao X, Jin C, Xue Y, Yao X: DOG 1.0: illustrator of protein domain structures. Cell Res 2009, 19:271-273.